Efficacy of Sadrava Udghaá¹?á¹£aá¹?a with Triphala CÅ«á¹?á¹?a and DhÄ?nyÄ?mla against Niá¹?drava Udghaá¹?á¹£aá¹?a with Triphala CÅ«á¹?á¹?a in Diabetic Distal Symmetric Polyneuropathy - A Randomized Controlled Clinical Trial

Start Date06 Jun 2022

Sponsor / Collaborator-

100 Clinical Results associated with Monophosphoryl lipid A

100 Translational Medicine associated with Monophosphoryl lipid A

100 Patents (Medical) associated with Monophosphoryl lipid A

690

Literatures (Medical) associated with Monophosphoryl lipid A

01 Sep 2025·EUROPEAN JOURNAL OF RADIOLOGY

Magnetic resonance imaging features of mesonephric-like adenocarcinoma of the uterine corpus in comparison with endometrial endometrioid carcinoma: Multi-institutional study

Article

Author: Yamada, Kaori ; Masuoka, Sota ; Fujiwara, Hiroyuki ; Matsuki, Mitsuru ; Fujii, Shinya ; Fukushima, Noriyoshi ; Fukui, Hideyuki ; Yamamoto, Saki ; Mori, Harushi ; Kato, Hiroki ; Fujii, Hiroyuki ; Himoto, Yuki ; Ueno, Yoshiko ; Tsuboyama, Takahiro ; Sano, Naoki ; Kihara, Atsushi ; Kikuchi, Tomohiro

PURPOSE:

To examine magnetic resonance imaging (MRI) features of mesonephric-like adenocarcinoma (MLA) of the uterine corpus.

METHOD:

MRI features of 19 patients with pathologically proven MLA of the uterine corpus were retrospectively compared with those of 95 patients with endometrial endometrioid carcinoma (EEC).

RESULTS:

Most patients with MLA were postmenopausal. Advanced FIGO stages were more common in the MLA than in the EEC group (63.2 % vs. 18.9 %, p < 0.001). On MRI, endophytic growth into the myometrium were more frequent in the MLA than in the EEC group (68.4 % vs. 14.7 %, p = 0.005). The median maximum tumor diameter in the MLA group (52.4 mm) tended to be larger than that in the EEC group (38.9 mm), although the difference was not statistically significant (p = 0.374). The tumor-to-muscle signal intensity ratio (SIR) on fat-suppressed gadolinium-enhanced T1-weighted gradient-echo imaging was higher in the MLA group than in the EEC group. (1.67 vs. 1.36, p = 0.002). The SIR on diffusion-weighted imaging (DWI) was comparable between the two groups (8.35 vs. 6.72, p = 0.330). The apparent diffusion coefficient value was lower in the MLA than in the EEC group (0.69 10^-3 mm²/s vs. 0.76 × 10^-3 mm²/s, p = 0.003). Coexisting adenomyosis was more frequent in the MLA than in the EEC group (52.6 % vs. 21.1 %, p = 0.034). The concordance rate between MRI and pathology for adenomyosis coexistence was 84.2 % for MLA, 87.4 % for EEC, and 86.8 % overall. MLA of the uterine corpus was identified in two patients, characterized by development independent of and discontinuous from the endometrium, whereas EEC in all patients demonstrated continuity with the endometrium.

CONCLUSIONS:

MRI of MLA of the uterine corpus typically demonstrates large, diffuse, and endophytic growth into the myometrium, with strong contrast enhancement and more restricted diffusion compared to EEC, with coexisting adenomyosis present in over 50% of patients. Therefore, postmenopausal women with adenomyosis should be carefully evaluated for MLA on MRI, particularly using DWI.

01 Sep 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Ciprofol attenuates sepsis-induced cardiomyopathy via α7 nicotinic acetylcholine receptor-dependent modulation of myocardial inflammation and NF-κB/STAT3 signaling

Article

Author: Kang, Wen ; Pan, Xia ; Zeng, Xin ; Zhou, Qin ; Xia, Zhongyuan ; Wang, Long

Sepsis-Induced Cardiomyopathy (SIC) is a life-threatening complication with limited therapies, significantly contributing to septic mortality. This study investigated the cardioprotective effects of ciprofol, a novel anesthetic, in SIC and elucidated the role of the α7 nicotinic acetylcholine receptor (α7nAChR) pathway. Using a cecal ligation and puncture (CLP)-induced murine sepsis model, we assessed ciprofol pretreatment's impact on myocardial injury, cardiac function, survival, and inflammation. The α7nAChR antagonist methyllycaconitine (MLA) was used to investigate pathway involvement. Our findings demonstrated that ciprofol pretreatment significantly mitigated sepsis-induced myocardial injury, evidenced by reduced serum creatine kinase-MB (CK-MB) and lactate dehydrogenase (LDH). Ciprofol also improved cardiac function, indicated by increased left ventricular ejection fraction (LVEF) and fractional shortening (FS), and markedly enhanced 14-day survival. These benefits were accompanied by attenuated cardiac inflammation, characterized by reduced myocardial infiltration of CD68⁺ macrophages (including pro-inflammatory CD86⁺ M1 phenotype) and myeloperoxidase (MPO) + neutrophils, alongside decreased systemic IL-6 and TNF-α. Crucially, MLA co-administration largely abrogated ciprofol's cardioprotective and anti-inflammatory effects. Mechanistically, ciprofol modulated α7nAChR signaling, inhibiting cardiac NF-κB p65 and STAT3 phosphorylation; MLA reversed these modulatory effects. In conclusion, ciprofol exerts significant cardioprotection against SIC, primarily via an α7nAChR-dependent pathway. This pathway suppresses myocardial inflammation by reducing inflammatory cell infiltration, cytokine production, and beneficially modulating NF-κB/STAT3 signaling. These insights suggest ciprofol's potential as an anesthetic with valuable organ-protective properties for critically ill septic patients.

01 Aug 2025·EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Intra-aortic infusion of nicotine can induce a novel mouse model of abdominal aortic aneurysm

Article

Author: Liu, Haole ; Xia, Congcong ; Tian, Kangli ; Liu, Enqi ; Xu, Baohui ; Cai, Tianzhi ; Zhao, Sihai ; Meng, Yibin ; Wei, Panpan ; Qin, Longlong ; Zou, Jiawei ; Malik, Fizza ; Hou, Haiwen ; Tian, Ruipu ; Li, Kexin

OBJECTIVE:

Smoking is one of the most important independent risk factors for abdominal aortic aneurysm (AAA). However, harmful tobacco substances, such as nicotine, are not directly used to induce experimental AAAs in animals to mimic smokers with an AAA status similar to that of humans. To facilitate the study of the relationship between smoking and AAA, this study presents a novel model of nicotine-induced AAA.

METHODS:

In the present study, Mendelian randomization (MR) analyses were used to validate that smoking and its main harmful substance, nicotine, are independent risk factors for AAA. We then evaluated the intraluminal infusion of four doses of nicotine into mouse abdominal aortas to establish a novel AAA model.

RESULTS:

MR analysis revealed that smoking, daily cigarette consumption, and smoking cessation history were positively associated with AAA pathogenesis, and the associations between the nicotine metabolism rate and AAA approached statistical significance. On day 14 after nicotine infusion in the mice, the mean diameter of the abdominal aorta increased from approximately 0.50 mm (baseline) to 0.94 to 1.0 mm in the four groups. Almost all of the mice developed abdominal aortic aneurysms, but aortic dilation did not show a clear dose‒dependent relationship. Compared with the sham and PBS infusion groups, the nicotine infusion group (5 mg/mL dose was selected for subsequent analysis) presented more severe aortic dilation, aortic elastin degradation, medial smooth muscle cell loss and aortic leukocyte accumulation. A more severe inflammatory status also increased aortic matrix metalloproteinase (MMP)2 and MMP9 expression and promoted mural neovessel sprouting. Notably, the lesions in the nicotine infusion group were generally not as severe as those in the PPE infusion group, which served as a positive control. To test whether the effect of nicotine on AAA pathogenesis is dependent on its corresponding receptors, we blocked its main receptor, the α7 subunit nicotinic acetylcholine receptor, with the antagonist methyllycaconitine (MLA). The results showed that the aneurysmal lesions were significantly improved by MLA treatment.

CONCLUSION:

In this study, we established a novel and highly efficient experimental AAA model via direct intraluminal nicotine infusion. We also demonstrated that nicotine-induced AAA formation is partially dependent on the activation of its receptors, thus providing a research tool for studying the management of smoking-induced AAAs.

News (Medical) associated with Monophosphoryl lipid A

21 Jul 2022

·www.biospace.com

HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate

BOSTON, July 20, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced results from NOR-213, a Phase 2 long-term immunogenicity follow-up clinical trial of adults and older adults who previously received HIL-214, the company’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. NOR-213 included 528 adult and older adult subjects that were enrolled following participation in prior clinical studies of HIL-214, including NOR-107, NOR-204, and NOR-210. The subjects received either one or two doses of HIL-214 (GI.1/GII.4 VLP combination with 500 µg alum) with or without the adjuvant monophosphoryl lipid A (MPL). Among all dose regimens of HIL-214, GI.1-specific and GII.4-specific HBGA-blocking and pan-Ig responses to vaccination persisted to year 5 of the study and, at year 5, results were similar to those previously reported at year 3. These results further support a single dose of HIL-214 (15/50 µg GI.1/GII.4 VLP combination with 500 µg alum) without MPL as the intended regimen for future development in adults and older adults. No adverse events were deemed related to HIL-214, and no new safety risks were identified during the study. The company anticipates presenting detailed data from the NOR-213 clinical trial at a future medical meeting. “We believe the data from this 5-year clinical study are very encouraging for the long-term immunogenicity and safety pro HIL-214,” said Astrid Borkowski, MD, PhD, Chief Medical Officer of HilleVax. “We look forward to the continued development of HIL-214 across the age spectrum, including our ongoing Phase 2b study in infants and future clinical studies in adults and older adults.” About HIL-214 HIL-214 is a bivalent vaccine candidate in development for the prevention of moderate-to-severe AGE caused by norovirus infection. HIL-214 consists of virus-like particles (VLPs) which are designed to mimic the structure of two major genotypes of norovirus, GI.1 and GII.4, and is co-formulated with an alum adjuvant. To date, HIL-214 has been studied in nine clinical trials which collectively generated safety data from more than 4,500 subjects and immunogenicity data from more than 2,200 subjects, including safety and immunogenicity data from more than 800 pediatric subjects. A randomized, placebo-controlled Phase 2b field efficacy trial enrolled 4,712 adult subjects, and HIL-214 was well tolerated and demonstrated clinical proof of concept in preventing moderate-to-severe cases of AGE from norovirus infection. A randomized, placebo-controlled Phase 2b field efficacy trial of 3,000 infant subjects is currently ongoing. We believe HIL-214 is the most advanced norovirus-related vaccine candidate in human clinical trials. About HilleVax HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

VaccineClinical Result

100 Deals associated with Monophosphoryl lipid A

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Immune System Diseases	Phase 3	-	Corixa Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Monophosphoryl lipid A

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation